Stem cells for cardiac repair: Problems and possibilities

Future Cardiology

Volumn 9, Issue 6, 2013, Pages 875-884

  Henning, Robert J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

bone marrow stem cell; c kit cells; cardiac stem cells; cardiosphere; cardiosphere derived cell; heart repair; myocardial infarction; stem cell

Indexed keywords

CELL THERAPY AGENT; HEPARIN; MYOCYTE ENHANCER FACTOR 2; PLACEBO; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5;

ACUTE HEART INFARCTION; BONE MARROW BIOPSY; BONE MARROW CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CELL MIGRATION; ERYTHROCYTE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC CARDIOMYOPATHY; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STEM CELL; THORAX PAIN;

HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RECOVERY OF FUNCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84887228297     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.78     Document Type: Review

References (44)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease study 2010. Lancet 380, 2095-2128 (2012).
2. Henning RJ. Stem cells in cardiac repair. Future Cardiol. 7, 99-117 (2011).
3. Henning RJ. Stem cells in cardiac repair - recent developments and future directions. Interv. Cardiol. 7, 10-13 (2012).
4. Traverse J, Henry TD, Ellis SG et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function. The LateTIME randomized trial. JAMA 306, 2110-2119 (2012). LateTIME trial of unfractionated bone marrow mononuclear cells.
5. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355, 210-221 (2006).
6. Traveres J, Henry TD, Pepine CJ et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction. The TIME randomized trial. JAMA 208, 2380-2389 (2012).
7. Suder D, Manka R, LoCicero V et al. Intracoronary injection of bone marrow derived mononuclear cells, early or late after acute myocardial infarction: Effects on global left ventricular function. Four month results of the SWISS AMI trial. Circulation 127, 1968-1979 (2013).
8. Meyer G, Wollert K, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction. Eighteen months' follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration) trial. Circulation 113, 1287-1294 (2006).
9. Solomon S, Skali H, Anavekar N et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 111, 3411-3419 (2005).
10. Richman S, Gee A, McKenna D et al. Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: A Cardiovascular Cell Therapy Research Network (CCTRN) study. Transfusion 52, 2225-2233 (2012).
11. Kissel C, Lehmann R, Assmus B et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol. 49, 2341-2349 (2007).
12. Fadini G, Boscaro E, De Kreutzenberg S et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of Type 2 diabetes. Diabetes Care 33, 1097-1102 (2010).
13. Orlandi A, Chavakis E, Seeger F, Tjwa M, Zeiher A, Dimmeler S. Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res. Cardiol. 105, 703-712 (2010).
14. Assmus B, Tonn T, Seeger F et al. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J. Am. Coll. Cardiol. 55, 1385-1394 (2010).
15. Seeger F, Rasper T, Fischer A et al. Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ. Res. 111, 854-862 (2012).
16. Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischaemic heart disease. Circulation 109, 1615-1622 (2004).
17. Murphy J, Cho Y, Sachpatzidis A, Fan C, Hodsdon M, Lolis E. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J. Biol. Chem. 282, 10018-10027 (2007).
18. Seeger F, Tonn T, Krzossok N, Zeiher A, Dimmeler S. Cell isolation procedures matter: A comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 28, 766-772 (2007).
19. Van Beem, Hirsch A, Lommerse I et al. Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. EuroIntervention 4, 133-138 (2008).
20. Hofmann M, Wollert K, Meyer G et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198-2202 (2005).
21. Hou D, Youssef E, Brinton T et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery. Circulation 112, I150-I156 (2005).
22. Henning RJ, Burgos J, Vasko M et al. Human cord blood cells and myocardial infarction: Effect of dose and route of administration on infarct size. Cell Transplant. 16, 907-917 (2007).
23. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776 (2003).
24. Kikuchi K, Poss K. Cardiac regenerative capacity and mechanisms. Ann. Rev. Cell Dev. Biol. 28, 719-741 (2012).
25. Kajstura J, Gurusamy N, Ogorek B et al. Myocyte turnover in the aging human heart. Circ. Res. 107, 1374-1286 (2010).
26. Bearzi C, Rota M, Hosoda I et al. Human cardiac stem cells. Proc. Natl Acad Sci. USA 104, 14066-14073 (2007).
27. Anversa P, Kajstura J, Rota M, Leri A. Regenerating new heart with stem cells. J. Clin. Invest. 123, 62-70 (2013).
28. Bolli R, Chugh A, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomized Phase 1 trial. Lancet 378, 1847-1857 (2011).
29. Chugh A, Beache G, Loughran J et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 126, S54-S64 (2012).
30. Bolli R, Chugh AR, Domenico D et al. Effect of cardiac stem cells in patients with ischemic cardiomyopathy: Interim results of the SCIPIO trial up to 2 years after therapy. Presented at: American Heart Association Scientific Sessions. Los Angeles, CA, USA, 3-7 November 2012.
31. Smith R, Barile L, Cho H. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomycardial biopsy specimens. Circulation 115, 911-917 (2007).
32. Tao-Sheng L, Cheng K, Malliaras K et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59, 942-953 (2012).
33. Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 106, 971-980 (2010).
34. Makkar R, Smith R, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomized Phase 1 trial. Lancet 379, 895-904 (2012).
35. Malliaras K, Cheng K, Smith R et al. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence for therapeutic regeneration in the final 1 year results of the CADUCEUS trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2013.08.724 (2013) (Epub ahead of print).
36. Murry C. Critique of the CADUCEUS trial. Presented at: American Heart Association Scientific Sessions. Los Angeles, CA, USA, 3-7 November 2012.
37. Kwong R, Farzaneh-Far A. Measuring myocardial scar by CMR. JACC Cardiovasc. Imaging 4, 157-160 (2011).
38. Bartunek J, Behfar A, Dolatabadi D et al. Cardiopoietic stem cell therapy in heart failure. The C-Cure (Cardiopoietic Stem Cell Therapy in Heart Failure) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61, 2329-2338 (2013).
39. Williams A, Hatzistergos K, Addicott B et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127, 213-223 (2013).
40. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002).
41. Roncarlo MG, Vaccarinom E, Saracco P et al. Cellular Characteristics of Cord Blood and Cord Blood Transplantation. Broxmeyer HE (Ed.). AABB Press, MD, USA (1998).
42. Assmus B, Walter D, Seeger F et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure. The CELLWAVE randomized clinical trial. J. Am. Med. Assoc. 309, 1622-1631 (2013).
43. Henning RJ, Dennis S, Sawmiller D et al. Human umbilical cord blood mononuclear cells activate the survival protein Akt in cardiac myocytes and endothelial cells that limits apoptosis and necrosis during hypoxia. Transl. Res. 159, 497-506 (2012).
44. Jin H, Sanberg P, Henning RJ. Human umbilical cord blood cells secrete growth factors and cytokines that inhibit hypoxic-induced apoptosis in coronary artery endothelial cells and cardiac myocytes by activation of the survival proteins Akt and Bcl-2. Cell Transplant. 22, 1637-1650 (2013).